{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:04Z","timestamp":1791343444224,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA 006516"],"award-info":[{"award-number":["CA 006516"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute Leukemia","award":["CA100632-11"],"award-info":[{"award-number":["CA100632-11"]}]},{"name":"Jock and Bunny Adams Research and Education Endowment"},{"name":"Analytical Pharmacology Core of the Sidney Kimmel Comprehensive Cancer Center"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UL1 RR025005"],"award-info":[{"award-number":["UL1 RR025005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["UL1RR025005"],"award-info":[{"award-number":["UL1RR025005"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.bbmt.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T19:35:02Z","timestamp":1410982502000},"page":"2042-2048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":209,"title":["Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"20","author":[{"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Valles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimalangshu R.","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trivikram","family":"Rajkhowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigitas","family":"Verselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.09.007_bib1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.007_bib3","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: ITDoes matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.007_bib4","first-page":"175","article-title":"Treatment of FLT3-ITD acute myeloid leukemia","volume":"1","author":"Fathi","year":"2011","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.bbmt.2014.09.007_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2014.09.007_bib6","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2005-03-1323","article-title":"No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials","volume":"106","author":"Gale","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/bmt.2012.88","article-title":"Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3\/ITD outweighs the conventional markers","volume":"47","author":"Sengsayadeth","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib8","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2006-09-047225","article-title":"Improved outcome after stem-cell transplantation in FLT3\/ITD-positive AML","volume":"109","author":"Bornhauser","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bbmt.2011.02.003","article-title":"Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution","volume":"17","author":"DeZern","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.bbmt.2012.06.012","article-title":"Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD","volume":"18","author":"Laboure","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.leukres.2012.10.005","article-title":"Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3","volume":"37","author":"Lin","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2014.09.007_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.09.007_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.007_bib14","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2006-04-015487","article-title":"The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib15","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":"A\u00a0FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in\u00a0vitro and in\u00a0vivo","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib16","doi-asserted-by":"crossref","first-page":"121a","DOI":"10.1182\/blood.V106.11.403.403","article-title":"A\u00a0randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition","volume":"106","author":"Levis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib17","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.007_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib19","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2002-02-0531","article-title":"SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase","volume":"100","author":"Yee","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib20","doi-asserted-by":"crossref","unstructured":"Cortes J, Foran J, Ghirdaladze D, et\u00a0al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. Blood (ASH Annual Meeting Abstracts) 2009,114:Abstract\u00a0636.","DOI":"10.1182\/blood.V114.22.636.636"},{"key":"10.1016\/j.bbmt.2014.09.007_bib21","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in\u00a0vitro and in\u00a0vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib22","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib23","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1182\/blood-2010-06-291104","article-title":"Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Yokoyama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib24","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bmt.2011.7","article-title":"Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib","volume":"47","author":"Kruger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib26","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/j.leukres.2010.04.011","article-title":"Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report","volume":"34","author":"Winkler","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2014.09.007_bib27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib28","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.09.007_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/10428194.2012.737917","article-title":"A\u00a0phase I\/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186","volume":"54","author":"Macdonald","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.09.007_bib30","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.007_bib31","doi-asserted-by":"crossref","unstructured":"Uy GL, Sanford B, Marcucci G, et\u00a0al. Initial results of a phase II trial of sorafenib plus standard induction in older adults with mutant FLT3 acute myeloid leukemia (AML) (Alliance Trial C11001). American Society of Hematology Annual Meeting 2013: abstract\u00a02653.","DOI":"10.1182\/blood.V122.21.2653.2653"},{"key":"10.1016\/j.bbmt.2014.09.007_bib32","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib33","doi-asserted-by":"crossref","first-page":"16741","DOI":"10.1073\/pnas.0506088102","article-title":"Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease","volume":"102","author":"Whartenby","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2014.09.007_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/eji.201242603","article-title":"Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects","volume":"43","author":"Klein","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2014.09.007_bib35","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1182\/blood-2008-06-161026","article-title":"Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment","volume":"113","author":"Swee","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib36","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.V99.5.1825","article-title":"Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease","volume":"99","author":"Teshima","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2011.08.011","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.09.007_bib39","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.09.007_bib40","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.09.007_bib41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911400562X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911400562X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:56Z","timestamp":1761058136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911400562X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S108387911400562X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}